||Special Issue 2015|
Celebrating More Than 20 Years of Continued Use: Levofloxacin Remains a Mainstay of Antimicrobial Therapy
Levofloxacin has maintained unparalleled activity since being developed in 1986 and introduced to the Japanese market in 1993. It has gone on to become a leading antimicrobial worldwide and, arguably the leading fluoroquinolone, due to its high potency, excellent tolerability, and ability to treat a wide range of infections.
Data has continued to accumulate highlighting the PK/PD advantages possessed by this remarkable agent, advantages that are reflected in its excellent clinical activity. Over this time, other fluoroquinolones have come onto the market, but none has matched levofloxacin in terms of maintaining excellent activity balanced with exceptional patient satisfaction.